“中国瓣膜第一股”启明医疗-B(2500.HK,下称“启明医疗”)近期发布了2024年财报,公司营收告别了两位数增长,同比下滑4.97%至4.7亿元,低于行业增速以及同行业可比公司的收入增速,也是公司自2019年港股主板上市后交出了最大营收降幅;净利润则是继续亏损,年内亏损达到7.17亿元,上市六年中,公司净利润合计“失血”超34亿元。作为曾经的明星企业,启明医疗经历过高光时刻:巅峰市值一度突破...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.